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INTRODUCTION 
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INTRODUCTION 
 
         
SLE is a chronic inflammatory disease of  unknown  aetiology 
which   involving multiple organs of the body .It mainly affects the  
women of child  bearing age group  and the ratio of 10 to 15:1 (female : 
male), mainly due to estrogen which modulates the lymphocyte 
activation1 . 
 
 
   The genetic susceptibility with environmental factor promotes 
immune system activation and damages the organ that contributes to the 
clinical manifestation, morbidity and occasionally mortality2,3.  
 
 
    There is an accelerated progression of atherosclerosis in patients 
with SLE due to chronic inflammation which promotes inflammatory 
mediators and cytokine release which leads to vascular and endothelial 
dysfunction causes decreased compliance of the blood vessels and  
promotes atheromatous plaque formation, The presence of thyroid 
dysfunction among SLE patients further aggrevates this condition.45 
 
 
3 
 
. 
 
 
                  
 
 
 
 
                    
 
 
           
AIMS AND OBJECTIVES 
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AIM AND OBJECTIVES 
 
 
 
 To study the prevalence of thyroid dysfunction in patients with 
SLE. 
 To measure Free T3, Free T4, TSH in serum. 
 To emphasize the role of routine thyroid function testing in patients 
with SLE. 
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REVIEW OF LITERATURE 
 
PREVALENCE: 
The prevalence of disease is more common in Asian , African-
American and Hispanic population which is three to four fold higher 
when compared to white populations .It is rare in African blacks  . Its 
prevalence rate ranges from 20 - 240 per 1,00,000 persons . 
 
HISTORICAL ASPECTS : 
The word "Lupus"as derived from  Latin word - ‘wolf’  which is 
coined  by a physician  Rogerius who  describes the  erosive lesion of 
face  which is a reminiscent of  wolf's bite  and "Erythematosus" from 
Greek word means red color. 4-7 The skin lesions are described by 
Thomas, Bateman, Cazenave and  Moriz Kaposi in nineteenth century.  
Kaposi proposed the two types of lupus erythematosus as discoid form 
and a disseminated form. The disseminated or systemic form of lupus was 
firmly established by the work of Osler in Baltimore and Jadassohn in 
Vienna in 1904 .8  
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PATHOGENESIS : 
 
 
 
 
 
 
The susceptible genes and environmental factors leads to abnormal 
immune system activation which includes, 
1) Abnormal activation pathways and decreased activation 
thresholds in adaptive immunity cells such as mature B 
lymphocytes and Tlymphocytes. 
2) Impaired clearence of apoptotic cells and immune complexes. 
3) Innate immune system activation y protein self antigen , viral  
RNA / DNA  
4) Defective regulation of B cells, CD4, CD8 and myeloid 
suppressor cells.   
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Due to this immune dysregulation there is increased production of   
Interleukin 17 and 10, Interferon 1 and 2, tumor necrosis factor α (TNFα), 
B cell maturation and cytokines B lymphocytes.  
There is decreased production of Interleukin 2 and Transforming 
growth factor β (TGF β ), all these factors contribute to autoantibody 
production and complement activation  leads to release of  inflammatory 
cytokines,  oxidants and vasoactive products which leads to target tissue 
damage in  multiple organs .9-12 
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AETIOLOGY  : 
 
 
Definite : 
 
Ultraviolet B light 13 
 
 
Probabale : 
 
Prolactin and Estrogen1 
 
 
Drugs :13 
 
 1)   Methyldopa 
 2)   Isoniazide 
 3)   Minocycline 
 4)   ACE inhibitor 
 5)   Beta blocker 
 6)   Hydantoins 
 7)   Hydralazine 
 8)   Procainamide 
 9)   Propafenone 
10)  Chlorpromazin 
11)  Penicillamine 
12)  Disopyramide 
13)  Interferon-α 
14)  Tumor necrosis factor inhibitors 
10 
 
 
POSSIBLE : 14-17 
1)  Smoking 
2)  Vitamin D deficiency 
3)  Infectious agents other than Epstein Bar Virus  
4)  HIV 
5)  Bacterial DNA 
6)  Bacterial lipopolysaccharides 
7)  Endotoxins 
8)  Silica 18 
9)  Pristane and other hydrocarbons 
 
 
DIETARY FACTORS : 
Alfalfa sprouts and canavanine  containing foods. 
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GENETIC FACTORS : 
 
 
 
 
12 
 
SYSTEMIC MANIFESTATIONS OF SLE : 
Systemic lupus erythematosus is an autoimmune disease with 
varying presentations from mild disease to life threatening disease 
characterised by relapsing and remitting course with multisystem 
involvement having variable prognosis. The comorbidities of SLE is 
described based on the system affected. 
MUCOCUTANEOUS  MANIFESTATIONS : 
It is the most common manifestation which occurs in 80 - 90%  
patients of SLE. Photosensitivity and oral ulcers are common in SLE 
patients. It is classified into lupus specific and lupus non specific skin 
lesions .19,20 
    LUPUS SPECIFIC SKIN LESION 
 
 
   Acute cutaneous             subacute cutaneous          chronic cutaneous 
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ACUTE CUTANEOUS  ERYTHEMATOSUS  :  
 
  
 
The butter fly rash is a hallmark of acute skin lesion and is 
confined to the malar area sparing nasolabial fold. The most commonly 
involved site is palmar, dorsal and extensor aspect of the hands. It  
classically involves the space between interphalangeal joints and spares 
the metacarpophalangeal  joints where it heals without scarring.19,20 
14 
 
 
SUBACUTE ERYTHEMATOSUS : 
 
 
 
 
It presents either as annular lesion with central clearing and 
peripheral scaling or papulosquamous lesion .It mainly affects shoulder, 
back, neck and extensors of the arm where it spares the face. The lesion 
lasts for weeks to months and is also non scarring .The antibody 
associated with annular type is anti-SSA/Ro, 21 where paraneoplastic 
syndrome is also associated with subacute  erythematous lesion.22 
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CHRONIC CUTANEOUS ERYTHEMATOSUS : 
 
 
 
 
 
 
The commonest type of chronic cutaneous lupus is discoid lupus 
erythematosus (DLE) which is further classified into generalised discoid 
involves above and below the neck, the other type is localised  
predominantly  affects  head and  neck. The lesion appears as disc shape 
so it is named as discoid. The characteristic finding is follicular plugging.  
Lupus profundus, lupus panniculitis  and chilblain lupus are other chronic 
cutaneous lupus lesions. It histologically resembles as  
squamous cell carcinoma .23 
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NON SPECIFIC LUPUS SKIN LESIONS : 
 
 Vasculitis 
 leg ulcer 
 cutis laxa 
 urticaria 
 Rheumatoid nodule 
 Sclerodactyl 
 Non scaring alopecia  
 Acanthosis nigricans 
 Erythema multiforme 
 Lichen planus 
 Non scaring bullous eruptions24 
 
 
 
NON SCARRING BULLOUS LESION which is a rare 
manifestation of systemic lupus erythematosus. 
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MUSCULOSKELETAL : 
Arthralgia and polyarthritis are the commonest manifestations. 
Joint deformities and erosions are rare in SLE25 . Myalgia is very 
common but myositis is rare .26 
Avasular necrosis of bone  can also occur in SLE .27 
 
RENAL : 
It is the most common cause for morbidity and mortality in SLE .28 
The clinical presentation varies  from asymptomatic proteinuria or 
hematuria to frank nephrotic syndrome or glomerulonephritis which is 
rapidly progressing with significant loss of renal function The lupus 
nephritis usually occurs within first three years of the disease .The 
pathological evidence occurs in 90% cases of SLE whereas the clinical 
nephritis develops only in 50% cases .It is necessary to screen for 
nephritis in patients with active SLE at regular three months interval 
period. The lupus nephritis is classified by International Society Of 
Nephrology.29 Renal biopsy is mandatory for SLE patients with nephritis 
.Most of the patients with lupus nephritis will prone for accelerated 
atherosclerosis over a period of years of  the disease so it is  necessary to  
control inflammation , hyperlipidemia  and blood pressure. 
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LUPUS NEPHRITIS CLASSIFICATION  : 
 
(INTERNATIONAL SOCIETY OF NEPHROLOGY AND RENAL 
PATHOLOGY SOCIETY) 29 
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A)  Normal glomerulus 
B)  Mesangial  proliferative (Type II) 
C) Proliferative Nephritis which shows mesangial and  
endocapillary hypercellularity with lobular appearance of  
glomerular tufts and patent capillary loops , (Type III -Focal ,  
Type IV - Diffuse ) 
D)  Membranous nephropathy (Type V) - the capillary walls are  
prominent and widely patent resembles "stiff structure with  
decreased compliance.                                                                                               
A B 
C D 
20 
 
 
 
 
 
 
 
 
E)  Fibrinoid necrosis with karyorrhexis in focal proliferative   
glomerulonephritis.  
F,G) Cellular crescents with endothelial proliferation and monocytes 
lining  Bowman’s capsule  with a predominantly mononuclear 
interstitial infiltrate. 
 H) Severe interstitial fibrosis and tubular atrophy. Tubular basement 
membrane thickening and epithelial degeneration with deposition 
of  collagenous connective tissue . 
 
E F 
G H 
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PULMONARY MANIFESTATIONS: 
   
Pleuritis is the commonest manifestation which occurs in 50% 
cases of SLE and correlates with active disease. 30  Other manifestations 
are pleural effusion pneumonitis,  diffuse alveolar haemorrhage , chronic 
interstitial lung disease, 31 shrinking lung syndrome 32 and pulmonary 
arterial hypertension . 
 
CARDIOVASCULAR SYSTEM : 
    
It usually involves pericardium , coronary arteries , valves and 
myocardium. Pericarditis manifests in more than 50% of  patients. 33  
Valvular insufficiency and Libman-Sacks endocarditis  can also occur in 
SLE patients .The risk of coronary artery disease is higher in patients 
with SLE due to chronic inflammation and oxidative damage to the 
arteries which accelerates  atherosclerosis . 
 
VASCULAR : 
   
The risk of vascular events are three to tenfold higher in SLE 
patients especially in women less than 49 years of age. Myocardial 
infarction, vasculitis,  transient ischaemic attacks and  stroke cases  have 
been described  in  SLE patients .37 
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GASTROINTESTINAL SYSTEM : 
 
Nausea, vomiting , diarrhoea and elevated liver enzymes can  occur 
in active disease of SLE . Auoimmune peritonitis , pancreatitis  and 
Intestinal vasculitis is more prevalent in SLE patients which produces life 
threatening  events  like ischaemia, perforations , bleeding and sepsis. 34,35 
 
 
HEMATOLOGY : 
 
Anaemia is more common in patients with SLE . It usually affects 
all three cell lineages. Autoimmunehemolytic anaemia, Idiopathic 
thrombocytopenic purpura, Lymphadenopathy and spleenomegaly  are 
also more common among SLE patients.36 
 
 
OCCULAR : 
 
Keratoconjunctivitis  sicca  is  the most  frequent  occular  
complication of SLE.37  Other  serious  manifestations  includes  optic 
neuritis  and  retinal vasculitis  which leads to blindness. 
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CENTRAL NERVOUS SYSTEM : 38 
 
 
 
 
THYROID AND SLE : 
 Thyroid dysfunction is more prevalent in patients with SLE when 
compared to the general population and is mainly due to the production of 
antibodies such as antithyroglobulin and antimicrosomal antibodies. SLE  
patients are  more prone for developing  hypothyroidsm  rather than  
hyperthyroidsm . 
24 
 
CLINICAL MANIFESTATION : 
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DIAGNOSTIC CRITERIA OF SLE : 
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ANTIBODIES IN SLE : 
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TREATMENT : 
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THYROID : 
ANATOMY AND DEVELOPMENT 
        
The name of thyroid was described from Greek word (thyreos- 
shield, eidos-form). It is the first endocrine gland to develop which occurs 
in the third week of gestation. It arises from floor of primitive pharynx. 
The gland is butterfly shape and is situated in the   anterior part of the 
neck extends from C5-T1 between the suprasternal notch and cricoid 
cartilage. The weight of the gland is 12-20 grams and is brownish red in 
colour with rich blood supply. It is composed of two lobes joined by 
isthmus. The thyroid medullary C cells arises from ultimobronchial body 
of neural crest .39
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HISTOLOGY : 
 
Gland is composed of hollow spheres, called colloid follicles. 
Squamous epithelial cells, cuboidal cells (follicle cells) Colloid fills the 
follicle cavities Follicle cells produce thyroglobulin ---- TH  
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PHYSIOLOGY : 
 
The synthesis of thyroid hormone usually starts during 11th week 
of gestation. It secretes two principle hormones, namely triiodothyronine 
(T3) and thyroxine (T4) where T3 is also secreted from the peripheral 
tissue by deiodination of T4. The thyroid gland contains follicular cells 
which secretes thyroglobulin, a precursor of thyroid hormones. The 
secretion of T4 is twenty times higher than T3 which is more active  
than T4 .40 
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THYROID AXIS : 41 
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HORMONE ACTION : 
 
 
 
 
Thyroid hormone enters into the nucleus of the cells which binds to 
DNA sequence termed as thyroid response elements (TRE) of  thyroid 
hormone receptors (TR), especially T3 has higher affinity for binding 
with receptor than T4. The hormone receptor complex either increases or 
decreases the gene expression which codes for enzyme that regulates cell 
function.42 
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SUBCLINICAL HYPOTHYROIDISM : 
 
The patients are clinically asymptomatic with elevated TSH level 
usually less than 10 mU/L  and low normal free T4  level . 
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CAUSES OF HYPOTHYROIDISM : 
PRIMARY HYPOTHYROIDISM: 
Acquired : 
Autoimmune  : Hashimotos thyroiditis (SLE ,RA ) 
Postablative thyroiditis 
Infitrative thyroid disorders : Amyloidosis , scleroderma ,  
Hemochromatosis , sarcoidosis , cystinosis , 
 Riedels struma, 
Endemic goitre 
 
Congenital : 
TSH receptor mutation 
Agenesis or Dysplasia of thyroid 
Organification disorders 
NIS or Pendrin mutations 
Idiopathic TSH unresponsiveness 
 
SECONDARY HYPOTHYROIDISM: 
• Hypothalamic disorders : trauma, tumors, infiltrative disease, 
idiopathic  
• Pituitary disorders : Sheehans syndrome, infitrative disorders, 
trauma, post surgery or irradiation , pituitay hormonal 
deficiency . Bexarotene treatment 
36 
 
TRANSIENT HYPOTHYROIDISM : 
Subacute thyroiditis 
Silent thyroiditis like postpartum thyroiditis 
After subtotal thyroidectomy or 131 I treatment in Graves disease . 
 
SYMPTOMS OF HYPOTHYROIDISM : 
 
 1.    Hair loss 
  
 2.    Hoarseness of voice 
 
 3.    Dry skin 
 
 4.    Impaired hearing 
 
 5.    Dyspnea 
 
 6.    Cold intolerance 
 
 7.    Weight gain 
 
 8.    Decreased appetite 
 
 9.    Poor memory 
 
10.   Tiredness , weakness 
 
11.    Menorrhagia 
 
12.    Paraesthesia 
 
13.    Hearing impairment 
 
14.    Constipation 
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SIGNS OF HYPOTHYROIDISM : 
 
1) Diffuse alopecia 
 
2) Dry coarse skin 
 
3) Peripheral edema 
 
4) Myxedema 
 
5) Carpal tunnel sydrome 
 
6) Bradycardia 
 
7) Delayed tendon reflexes 
 
8) Polyserositis 
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TPO -     - Thyroid peroxidase antibody  present 
TPO +     -  Thyroid peroxidase antibody  absent 
TSH       -   Thyroid stimulating hormone 
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TREATMENT OF HYPOTHYROIDISM: 43 
 
Subclinical hypothyroidism : 
 
• If the TSH is persistently elevated for more than 3 months start 
treatment with levothyroxine 25-50 microgram. 
• In pregnancy treatment has to be initiated immediately. 
 
Overt Hypothyroidism : 
• Levothyroxine 1.6microgram per kg usually 100 -150µg, should be 
taken 30 minutes before breakfast. 
• Goal of the treatment is to normalise the TSH. 
 
Myxedema coma :44 
Levothyroxine IV - 500microgram as a loading dose, then followed 
by 50-100microgram/day plus parenteral hydrocortisone of 50mg every 
6th hourly. 
Treat hypothermia and electrolyte disturbances like hyponatremia 
or hypoglycemia. 
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CAUSES OF HYPERTHYROIDISM : 
 
PRIMARY HYPERTHYROIDISM : 
 
 
1) Graves disease 
 
2) Toxic adenoma 
 
3) Toxic multinodular goitre 
 
4) Jod-Basedow effect  (iodide induced ) 
 
5) Drug induced - Lithium , Amiodarone 
 
6) Struma ovarii 
 
7) Iatrogenic over replacement 
 
8) TSH receptor mutation 
 
9) McCune - Albright syndrome (mutation of Gsα) 
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SECONDARY HYPERTHYROIDISM : 
1) Pituitary tumors - TSH secreting tumors 
2) Pregnancy 
 3) Chorionic gonadotropin secreting tumors 
 
 
THYROTOXICOSIS WITHOUT HYPERTHYROIDISM : 
 
1) Silent thyroiditis 
2) Subacute thyroiditis 
3) Thyrotoxicosis factitia 
4) Radiation 
 
 
SUBCLINICAL HYPERTHYROIDISM : 
It is referred as, clinically asymptomatic patient with normal free 
thyroid hormones and subnormalTSH level  which is <0.1 mU/L .It can 
progress to hyperthyroidism if not recognized ealier and treated promptly. 
The prevalence is about 0.7% of the population. 
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SYMPTOMS OF HYPERTHYRODISM :45 
 
1) Fatigue and weakness 
2) Excessive sweating 
3) Heat intolerance 
4) Weight loss 
5) Increased appetite 
6) Palpitations 
7) Irritability  
8) Hyperactivity 
9)  Dysphoria 
10) Polyuria 
11) Diarrhoea 
12) Loss of libido 
13) Oligomenorrhea 
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SIGNS : 
 
1) Tremor 
2) Warm and moist skin 
3)Tachycardia 
4) Atrial fibrillation 
5) Gynecomastia 
6) Goitre 
7) Lid retraction or lag 
8) Proximal myopathy 
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45 
 
   
 
 
 
 
 
 
 
MATERIALS & METHODS 
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MATERIALS AND METHODS 
 
SOURCE OF DATA : 
Patients admitted in Department of Rheumatology , Madras 
Medical college and Rajiv Gandhi Government General Hospital , 
Chennai -3 diagnosed to have systemic lupus erythematosus , fulfilling 
the inclusion and exclusion criteria were included in the study group .100 
such patients were taken up for this study . 
 
STUDY DESIGN : 
A  hospital based observational study  
 
STUDY DURATION : 
6 months   
 
INCLUSION CRITERIA : 
Proven cases of Systemic lupus erythematosus by clinical and 
biochemical evidence . 
 
EXCLUSION CRITERIA : 
Patients with known case of  hypothyroidism , hyperthyroidism 
SLE patients with thyroid disorder on treatment. 
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DATA COLLECTION AND METHODS : 
Data was collected in a pretested proforma from eligible patients. 100 
patients were selected on the basis of simple random sampling. They 
were subjected to detailed history taking and clinical examination. The 
following investigations were done. 
 
 Haemogram 
 ESR 
 LFT 
 RFT with electrolytes 
 Urine Routine 
 Lipid profile 
 Electrocardiogram 
 Chest X -ray 
 ANA 
 Anti ds-DNA 
 Free T3 
 Free T 4 
 TSH 
 USG Neck 
 
 
48 
 
THYROID FUNCTION TEST : 
Thyroid function test was done by a single vein puncture and the 
blood sample is collected for assessing thyroid function by measuring 
FT3,FT4 and TSH level using radioimmunoassay method .The most 
accurate test to diagnose hypothyroidism and hyperthyroidism is serum 
TSH level where it is the first hormone to be affected in thyroid gland 
failure.I t usually depends upon the thyroid hormone level in the serum , 
so it is better to assess the TSH level along with T4 orT3 .FT4 is the 
physiological active form where it enters into the tissue and acts within it. 
The last hormone to be affected in thyroid disorder is T3 . 
• TSH level is elevated in hypothyroidism and decreased in 
hyperthyroidism. 
• FT3 and FT4 level decreased in hypothyroidism and increased  
in hyperthyroidism . 
• Normal FT4 -0.7-1.7ng/d 
• Normal FT3 -0.2-0.5ng/dl 
• Normal TSH -0.4-4.2mU/L   
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STASTICAL METHODS APPLIED : 
 
Datas were analysed using the SPSS software. Stastical 
significance was indicated by the Chisquare test. Variables were 
considered to be significant if p<0.05. 
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OBSERVATION AND RESULTS 
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OBSERVATION 
 
AGE DISTRIBUTION 
 
 
AGE Frequency Percent 
15-20 18 18.0 
20-30 45 45.0 
30-40 31 31.0 
40-50 6 6.0 
Total 100 100.0 
 
 
 
 
 
Most cases of SLE (45 Patients) occur in the age group of 20-30    
(45%) years. 
 
15%
16% 16%
17% 17%
10%
6%
2%
1%
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
NEW 1 2 3 4 5 6 7 8
Age distribution
NEW
1
2
3
4
5
6
7
8
  
 
Valid 
 
 
 
 
Among 100 patients included in our study, 20  (20%) patients had 
weight gain. 
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WEIGHT GAIN 
Frequency Percent
No 80 80.0
Yes 20 20.0
Total 100 100.0
 
80%
20%
WEIGHT GAIN
 
 
 
 
 
No
Yes
  
 
 
 
In our study  13 (13%)  patients  of SLE were
loss. 
 
 
 
Valid Yes
Total
53 
 
WEIGHT LOSS 
 
 found to have weight 
87%
13%
WEIGHT LOSS
Frequency Percent
No 87 87.0
 13 13.0
 100 100.0
 
No
Yes
 
 
 
 
  
 
Valid 
 
 
 
Out of 100 patients of SLE, heat intolerance was seen in 2 (2%)  
patients . 
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HEAT INTOLERANCE 
 
Frequency Percent
No 98 98.0
Yes 2 2.0
Total 100 100.0
 
 
98%
2%
HEAT INTOLERANCE
 
 
 
 
 
No
Yes
Valid 
 
 
  
In our study, cold intolerance was present in 13 (13%) patients of 
SLE. 
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COLD INTOLERANCE 
 
 Frequency Percent
No 87 87.0
Yes 13 13.0
Total 100 100.0
 
87%
13%
COLD INTOLERANCE
 
 
 
 
 
No
Yes
  
 
Valid 
No
Yes
Total
 
 
 
  
Among 100 patients of SLE, 
patients . 
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PALPITATION 
Frequency Percent 
 92 92.0 
 8 8.0 
 100 100.0 100.0
 
palpitation was seen in 8 (8%) 
 
92%
8%
PALPITATION
 
 
 
 
 
No
Yes
Valid
 
 
 
 
 
 
Out of 100 SLE patients, tremor was observed in 3 (3%) patients.
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TREMOR 
 Frequency Percent
 
No 97 97.0 
Yes 3 3.0 
Total 100 100.0
97%
3%
TREMOR
 
 
 
 
No
Yes
  
 
 
Valid 
 
 
 
In our study, skin manifestations was present in 5 (5%) patients.
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SKIN CHANGES 
Frequency Percent
No 95 95.0
Yes 5 5.0
Total 100 100.0
 
95%
5%
SKIN CHANGES
 
 
 
 
 
 
No
Yes
  
MENSTRUAL DISTURBANCES
 
Valid 
 
Out of 100 patients of SLE , menstrual disturbances 
11 (11%) patients . 
 
MENSTRUAL DISTURBANCES
59 
 
 
 
Frequency Percent
No 89 
Yes 11 
Total 100 100.0
 
 
 
89%
11%
 
89.0 
11.0 
 
 
was found in 
No
Yes
 Valid Diarrhea/constipation
 
 
 
 
In our study, GIT disturbances like diarrh
present in 9 (9%) patients.
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GIT 
 Frequency 
No 91 
 9 
Total 100 
ea and constipation was 
 
91%
9%
GIT
No
Diarrhea/constipation 
Percent 
91.0 
9.0 
100.0 
 
 PSYCHIATRIC
 
Valid 
 
 
 
Out of 100 patients of SLE, psychiatric manifestations mainly 
depression was seen in 7 (7%) patients.
 
PSYCHIATRIC MANIFESTATION
61 
 
 MANIFESTATION
Frequency Percent
No 93 93.0
Yes 7 7.0
Total 100 100.0
 
 
93%
7%
 
 
 
 
 
 
No
Yes
  
DYSLIPIDEMIA
 
Valid 
 
 
 
In our study, 12 (12%)  patients of SLE  had  dyslipidemia.
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Frequency Percent
No 88 88.0
Yes 12 12.0
Total 100 100.0
88%
12%
DYSLIPIDEMIA
 
 
 
 
 
 
No
Yes
  
 
Valid 
 
 
Among 100 patients of SLE, pleural effusion in Chest X
present in 3 (3%) patients.
63 
 
CHEST XRAY 
 
Frequency Percent
N 97 97.0
PE 3 
Total 100 100.0
 
 
97%
3%
CHEST X RAY
 
 
3.0 
 
 
-ray was 
N
PE
 THYROID HORMONE LEVEL
 
 
Valid 
Euthyroid state(<4.5)
subclinical hypothyroidism 
(TSH 
hypothyroidism(>10)
 
 
 
Among 100 patients of SLE, 8 (8%) patients were found to have 
overt hypothyroidism,
and 75 (75%) patients were in euthyroid state.
 
17%
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Frequency
 75 
 
-5-10) 17 
 8 
Total 100 
 17 (17%) patients have subclinical hypothyroidism 
 
75%
8%
Thyroid Hormone Level
Euthyroid state(<4.5)
subclinical hypothyroidism 
(TSH 
hypothyroidism(>10)
 Percent 
75.0 
17.0 
8.0 
100.0 
 
-5-10)
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RESULTS 
 
AGE GROUP - CROSS TABULATION 
 
 
THYROID 
Total Euthyroid 
state(TSH<
4.5) 
Subclinical 
hypothyroi
dism (TSH 
-5-10) 
Hypothyroi
dism 
(TSH>10) 
ag
e
_g
ro
up
 
15-20 
Count 17 0 1 18 
% within 
THYROID 22.7% 0.0% 12.5% 18.0% 
20-30 
Count 30 10 5 45 
% within 
THYROID 40.0% 58.8% 62.5% 45.0% 
30-40 
Count 23 6 2 31 
% within 
THYROID 30.7% 35.3% 25.0% 31.0% 
40-50 
Count 5 1 0 6 
% within 
THYROID 6.7% 5.9% 0.0% 6.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square  = 6.598  P>0.05 
 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22%
0%
13%
40%
59%
63%
31%
36%
24%
7%
5%
0%
0%
10%
20%
30%
40%
50%
60%
70%
Euthyroid state(TSH<4.5) Subclinical hypothyroidism 
(TSH -5-10)
Hypothyroidism(TSH>10)
Age distribution
15-20
20-30
30-40
40-50
67 
 
 
 
 
CORRELATION BETWEEN WEIGHT GAIN AND 
THYROID DYSFUNCTION IN SLE PATIENTS 
 
 
WEIGHT GAIN CROSS TABULATION : 
 THYROID Total 
euthyroid 
state(<4.5) 
subclinical 
hypothyroi
dism (TSH 
-5-10) 
hypothyroi
dism(>10) 
WEIGHT 
GAIN 
No 
Count 59 15 6 80 
% within 
THYROID 78.7% 88.2% 75.0% 80.0% 
Yes 
Count 16 2 2 20 
% within 
THYROID 21.3% 11.8% 25.0% 20.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square =0.929  P>0.05 
 
 
 
 
    
 
 
In our study, weight gain was observed in 
euthyroid state, 12% of cases in subclinical hypothyroidism and 25 % 
patients of overt hypothyroidism whic
p-value 0.929. 
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CORRELATION BETWEEN WEIGHT LOSS AND 
THYROID DYSFUNCTION IN SLE PATIENTS 
 
WEIGHT LOSS 
Crosstab 
 THYROID 
Total TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
WEIGHT 
LOSS 
No 
Count 63 17 7 87 
% within 
THYROID 84.0% 100.0% 87.5% 87.0% 
Yes 
Count 12 0 1 13 
% within 
THYROID 16.0% 0.0% 12.5% 13.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 
100.0
% 
Pearson Chi-Square =3.139 P>0.05 (0.208) 
 
 
 
 
 
  
In our study, the correlation between weight loss and thyroid 
dysfunction was observed. It was
euthyroid state, 12% of patients in overt hypothyroidism and was not 
present in subclinical hypothyroidism 
significant with p-value 0.208.
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 stastically  
Yes
No
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CORRELATION  BETWEEN HEAT INTOLERANCE AND 
THYROID DYSFUNCTION IN PATEINTS WITH SLE 
 
 
HEAT INTOLERANCE 
Crosstab 
 THYROID 
Total TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
HEAT 
INTOLERANCE 
No 
Count 73 17 8 98 
% within 
THYROID 97.3% 100.0% 100.0% 98.0% 
Yes 
Count 2 0 0 2 
% within 
THYROID 2.7% 0.0% 0.0% 2.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =0.680 P>0.05(0.712) 
  
 
 
In our study, the presence of heat 
patients with thyroid disorder.
correlation between heat into
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intolerance was observed in 
 It was found that there was no significant 
lerance and thyroid dysfunction.
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CORRELATION BETWEEN COLD INTOLERANCE AND 
THYROID DYSFUNCTION IN PATEINTS WITH SLE 
 
Cross tabulation 
 THYROID Total 
euthyroid 
state(<4.5) 
subclinical 
hypothyro
idism 
(TSH -5-
10) 
hypothyro
idism(>10) 
COLD 
INTOLE
RANCE 
No 
Count 64 17 6 87 
% within 
THYROID 85.3% 100.0% 75.0% 87.0% 
Yes 
Count 11 0 2 13 
% within 
THYROID 14.7% 0.0% 25.0% 13.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =3.743  P>0.05 
 
 
 
  
 
 
In our study, cold intolerance was seen in 15% of patients in 
euthyroid state and 25 % of patients with overt hypothyroidism which 
was stastically insignificant with  p
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CORRELATION BETWEEN PALPITATION AND THYROID 
DYSFUNCTION IN PATEINTS WITH SLE 
 
PALPITATION  
 
Crosstab 
 THYROID 
Total TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
PALPITATION 
No 
Count 68 17 7 92 
% within 
THYROID 90.7% 100.0% 87.5% 92.0% 
Yes 
Count 7 0 1 8 
% within 
THYROID 9.3% 0.0% 12.5% 8.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =1.880 P>0.05 (0.391) 
 
 
 
 
  
In our study, the presence of palpitation and thyroid dysfunction 
was found to have statically
 
 
 
82%
84%
86%
88%
90%
92%
94%
96%
98%
100%
76 
 
 insignificant with p-value - 0.391 .
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CORRELATION BETWEEN TREMOR AND THYROID 
DYSFUNCTION IN PATEINTS WITH SLE 
TREMOR 
Crosstab 
 THYROID Total 
TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
TREMOR 
No 
Count 72 17 8 97 
% within 
THYROID 96.0% 100.0% 100.0% 97.0% 
Yes 
Count 3 0 0 3 
% within 
THYROID 4.0% 0.0% 0.0% 3.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =1.031  P>0.05(0.597) 
 
 
 
  
 
In our study,
dysfunction was observed and found to have 
with p-value - 0.597
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 the correlation between tremor and thyroid 
statistically
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 insignificant 
Yes
No
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CORRELATION BETWEEN SKIN CHANGES AND THYROID 
DYSFUNCTION IN PATEINTS WITH SLE 
 
Cross tabulation 
 
THYROID 
Total euthyroid 
state(<4.5
) 
subclinica
l 
hypothyr
oidism 
(TSH -5-
10) 
hypothyr
oidism(>1
0) 
SKIN 
CHANGES 
No 
Count 71 17 7 95 
% within 
THYROID 94.7% 100.0% 87.5% 95.0% 
Yes 
Count 4 0 1 5 
% within 
THYROID 5.3% 0.0% 12.5% 5.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square =1.860 P>0.05 
 
 
 
 
  
 
 
 
In our study,
thyroid dysfunction and it was present in 12% of patients with overt 
hypothyroidism  with insignificant p
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 skin changes was observed in patients of SLE with 
-value >0.05 
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CORRELATION  BETWEEN  MENSTRUAL DISTURBANCES 
AND THYROID DYSFUNCTION IN PATEINTS WITH SLE 
 
MENSTRUAL DISTURBANCES 
 
Crosstab 
 THYROID Total 
TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
MENSTRUAL 
DISTURBANCES 
No 
Count 65 17 7 89 
% within 
THYROID 86.7% 100.0% 87.5% 89.0% 
Yes 
Count 10 0 1 11 
% within 
THYROID 13.3% 0.0% 12.5% 11.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =2.537 P>0.05(0.281) 
 
 
 
  
 
 
In our study,
patients of SLE with overt hypothyroidism and euthyroid state (12%)  
with insignificant  p
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 menstrual disturbances was equally distributed among 
-value0.281 . 
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CORRELATION BETWEEN GIT DISTURBANCES AND 
THYROID DYSFUNCTION IN PATEINTS WITH SLE 
 
GIT 
 
Crosstab 
 THYROID 
Total 
euthyroid 
state(<4.5) 
subclinical 
hypothyroi
dism (TSH 
-5-10) 
hypothyroi
dism(>10) 
GIT 
No 
Count 68 17 6 91 
% within 
THYROID 90.7% 100.0% 75.0% 91.0% 
Cons
tipati
on/ 
Diarr
hea 
Count 7 0 2 9 
% within 
THYROID 9.3% 0.0% 25.0% 9.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square =4.192 P>0.05 
 
 
 
  
 
In our study, GIT disturbances was observed in 9% of patients with 
normal thyroid function and 25% of patients with overt hypothyroidism.
It was found to have 
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statically insignificant with p-value >0.05
E
u
th
y
ro
id
 s
ta
te
(T
S
H
<
4
.5
)
S
u
b
cl
in
ic
a
l h
y
p
o
th
y
ro
id
is
m
 (
T
S
H
 -
5
-1
0
)
H
y
p
o
th
y
ro
id
is
m
(T
S
H
>
1
0
)
91% 100%
75%
9% 0%
25%
GIT distribution
No
 
 
 
85 
 
 
 
CORRELATION  BETWEEN  PSYCHIATRIC 
MANIFESTATIONS AND THYROID DYSFUNCTION  
IN PATEINTS WITH SLE 
PSYCHIATRIC MANIFESTATION 
Crosstab 
 THYROID Total 
TSH 
<4.5 
TSH 4.5-
10 
TSH 
>10 
PSYCHIATRIC 
MANIFESTATION 
No 
Count 70 17 6 93 
% within 
THYROID 93.3% 100.0% 75.0% 93.0% 
Yes 
Count 5 0 2 7 
% within 
THYROID 6.7% 0.0% 25.0% 7.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =5.274  P>0.05(0.072) 
 
  
 
 
In our study, psychiatric manifestation
overt hypothyroidism and 7% of patients with normal thyroid function.
was found that there was no stastical significance with p
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 was seen in 25% of cases of 
-value 0.072.
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CORRELATION BETWEEN DYSLIPIDEMIA AND          
THYROID DYSFUNCTION IN PATEINTS  
WITH SLE 
DYSLIPIDEMIA 
  Cross tabulation 
 THYROID 
Total euthyroid 
state(<4.5
) 
subclinica
l 
hypothyr
oidism 
(TSH -5-
10) 
hypothyr
oidism(>1
0) 
D
Y
SL
IP
ID
EM
IA
 
No 
Count 67 15 6 88 
% within 
THYROID 89.3% 88.2% 75.0% 88.0% 
Yes 
Count 8 2 2 12 
% within 
THYROID 10.7% 11.8% 25.0% 12.0% 
Total 
Count 75 17 8 100 
% within 
THYROID 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square =1.407  P>0.05 
 
 
  
 
In our study, the occurence of 
patients with overt hypothyroidism,
hypothyroidism and 11% cases of euthyroid state with insignificant 
p-value >0.05  
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dyslipidemia was seen in 25% of 
 12% of patients with subclinical 
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PREVALENCE OF CLINICAL SYMPTOMS AMONG
PATIENTS OF SLE WITH THYROID DYS
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DISCUSSION 
 
Our study was conducted in patients with SLE to know the 
prevalence of thyroid dysfunction. Our study population included 100 
patients, those who are fitting into the diagnostic criteria of SLE assessed 
by clinical and biochemical evidence .All the 100 patients were evaluated 
and screened for the presence of thyroid dysfunction .Analysis was made 
to establish the correlation between the prevalence of thyroid dysfunction 
and its clinical correlation by using Chi-square test. Following were the 
observations made in our study with the patients of SLE . 
 
Age distribution : 
In 100 patients of SLE, majority cases of subclinical and clinical 
hypothyroidism were in the age group of 20 - 30 years adults . 
 
Clinical features : 
Weight Gain : 
Out of 100 patients studied ,it  was present in 16 (21%) cases of 
euthyroid patients , 2 (12%)  cases of subclinical hypothyroidism and 2 
(25%) cases of clinical hypothyroidism  . 
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Weight Loss : 
Among 100 patients, 12 (16%) patients of euthyroid and 13 
(13%)patients of clinical hypothyroidism had weight loss . There is no 
significant weight loss observed in subclinical hypothyroidism. 
 
Heat Intolerance : 
In 100 patients of SLE, it was observed only in 2 (3%) patients of 
euthyroid and not observed in subclinical and clinical hypothyroidism. 
 
Cold Intolerance : 
Out of 100 patients studied, 11 (15%) cases of euthyroid had cold 
intolerance. 
 
Palpitation : 
Among 100 patients studied, palpitation was seen in 7(9%) patients 
of euthyroid and 1 (12%) patient of clinical hypothyroidism . 
 
Tremor : 
It was observed only in 3 (4%) patients of euthyroid patients ,  not 
observed in subclinical and clinical hypothyroidism . 
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Skin changes : 
Out of 100 patients, it was seen in 12 (12.5%) patients of clinical 
hypothyroidism and 4 (5%) of SLE patients with normal thyroid 
functional  status .   
 
Menstrual Disturbances : 
Out of 100 patients, menstrual disturbances was observed in 10 
(13%) patients of euthyroid and 1(12%)  patient of clinical 
hypothyroidism. 
 
GIT Symptoms : 
In our study, 7(9%) cases of euthyroid had diarrhea and 
constipation  whereas 2(25%) patients of clinical hypothyroidism had 
GIT disturbances . 
 
Psychiatric manifestations : 
Among 100 patients studied, psychiatric manifestations was 
observed in 5(7%) patients of SLE without thyroid dysfunction and 
2(25%)  patients of clinical hypothyroidism . 
 
Dyslipidemia : 
It was present in 8(11%) patients of normal thyroid function 
whereas  2(25%) cases of subclinical and 2(12%) patients of clinical 
hypothyroidism . 
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THYROID  DYSFUNCTION  IN SLE : 
 
Out of 100 patients in our study, 25 patients were found to have 
thyroid dysfunction. Most of the patients of SLE with thyroid dysfunction  
were clinically asymptomatic and  symptoms are present even in patients 
with feuthyroid state . 
 
In this study the prevalence of thyroid dysfunction and its clinical 
correlation  was done among the 100 patients of  SLE and this study was 
comparable to studies conducted  by  Kakehasi et al 46, Zakeri and  
Sandooghi 47 , Sahin et al 48 . 
 
 It was observed that the prevalence of subclinical hypothyroidism 
was slightly higher in our study which was about 17%, followed by 
clinical hypothyroidism 8%. In our study no subclinical and clinical 
hyperthyroidism case was observed. 
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CONCLUSION 
 
Following results were concluded from our study ; 
 
 SLE was more commonly seen in females of child bearing age 
group in the third decade. 
 The occurrence of weight gain was observed mainly in patients of 
SLE with euthyroid state and clinical hypothyroidism. 
 The incidence of weight loss in our study was present equally 
among the patients of SLE with euthyroid and clinical 
hypothyroidism. It was not found in patients of subclinical 
hypothyroidism. 
 There was no stastical significant correlation was observed 
between the presence of heat intolerance and thyroid dysfunction in  
patients with SLE  
 Cold intolerance was not seen significantly in patients of SLE with 
thyroid dysfunction. 
 It was observed that, the occurrence of palpitation was not 
significantly present among the patients of SLE with thyroid 
abnormalities. 
 Tremor was noted only in few cases of euthyroid and not observed 
in patients with thyroid dysfunction. 
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 Skin manifestations were present in few cases of clinical 
hypothyroidism and it was not correlating significantly in patients 
with thyroid dysfunction. 
 The presence of menstrual disturbances was distributed equally in 
patients of SLE with euthyroid state and clinical hypothyroidism  
 Most of the patients with clinical hypothyroidism was found to 
have GIT disturbances mainly diarrhea and constipation. 
 Among the patients of SLE with thyroid dysfunction the 
psychiatric manifestations are more commonly present in clinical 
hypothyroidism. 
 In our study nearly quarter of the patients with subclinical 
hypothyroidism had  dyslipidemia  
 
In our study the symptoms are not correlating significantly and it 
was difficult to clinically detect the presence of  thyroid dysfunction 
among patients with SLE because of the similarity of certain clinical 
symptoms which occurred both in  SLE and thyroid  disorder . 
 
The prevalence of subclinical hypothyroidism and clinical 
hypothyroidism among patients in SLE was clinically significant. 
 
The occurrence of subclinical and clinical hyperthyroidism was not 
significant in our study. 
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SUMMARY 
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SUMMARY 
SLE is an autoimmune disorder of unknown aetiology affects any 
system of the body.    
 
Development of thyroid dysfunction mainly autoimmune 
thyroiditis is more prevalent in SLE patients when compared to the 
general population. However this may be unnoticed because of the 
similarity of clinical manifestations between SLE and thyroid disorders .  
 
The prevalence of thyroid dysfunction in patients with SLE is more 
common when compared to the general population.  SLE patients with 
thyroid disorder are more prone for increased risk of cardiovascular 
disease because of accelerated atherosclerosis. 
 
The cardiovascular risk is independent of lipid profile parameters. 
 
The routine screening of patients with SLE for thyroid dysfunction 
is essential which helps in early detection and treatment of thyroid 
disorder. 
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ANNEXURES 
 
 
 
 
 
  
"ASSESSMENT OF THYROID FUNCTION IN PATIENTS WITH  
SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS  
CLINICAL CORRELATION " 
 
                                         PROFORMA 
NAME:                                                                    AGE/SEX  : 
ADDRESS :                                                            OCCUPATION : 
PRESENTING COMPLAINTS : 
• Fever 
• Joint pain 
• Easy fatiguability 
• Breathlessness / Orthopnea 
• Paroxysmal nocturnal dyspnea 
• Abdominal pain / abdominal distension 
• Heat intolerance 
• Cold intolerance 
• Weight gain 
• Weight loss 
• Nervousness 
• Palpitation 
• Tremor 
• Seizure 
• Altered sensorium 
• Constipation 
• Menstrual disturbances 
• Skin rash 
• Oral ulcer 
• Photosensitivity 
• Drug intake 
 
PAST HISTORY: 
• Heart disease 
• Hypertension 
• Diabetes 
• Pulmonary tuberculosis 
• Bronchial asthma 
• Epilepsy 
 
GENERAL EXAMINATION : 
 
• Built 
• Nourishment 
• pallor 
• Icterus 
• Cyanosis 
• Clubbing 
• Lymphadenopathy 
• Pedal edema 
• Oral cavity 
• Skin manifestations 
• Thyroid 
 
 
VITAL SIGNS : 
PR- 
BP- 
RR- 
 
SYSTEMIC EXAMINATIONS : 
 
CARDIOVASCULAR SYSTEM : 
 
RESPIRATORY SYSTEM: 
 
PER ABDOMEN: 
 
CENTRAL NERVOUS SYSTEM: 
 
INVESTIGATIONS : 
• Haemogram 
• ESR 
• Renal function test 
• Liver function test 
• Urine routine 
• Lipid profile 
• Electrocardiogram 
• Chest X-ray 
• Anti nuclear antibody 
• Anti ds -DNA 
• FreeT3 and Free T4 
• TSH 
• USG Neck 
 
ABBREVATIONS 
 
ACE   -  Angiotensin Converting Enzyme   
ANA   -  Anti nuclear Antibody 
Anti ds DNA -  Anti double stranded DNA 
Anti-Sm  -  Anti Smith   
APC   -  Antigen Presenting Cells  
CoA   -  Coactivators 
CoR   -  Co -Receptor protein 
DIT   -  Diiodotyrosine                    
ECG   -  Electrocardiogram 
GIT   -  Gastrointestinal Tract 
FT3   -  Free Triiodothyronine 
FT4   -  Free thyroxine    
HLA   -  Human Leukocyte Antigen   
IIF   -  Indirect Immunofluorescence     
LFT   -  Liver function test 
MHC   -  Major Histocompatibility Complex     
MIT   -  Monoiodotyrosine  
NO   -  Nitric oxide    
PE   -  Pleural effusion 
RA   -  Rheumatoid Arthritis  
 RFT   -  Renal function test 
ROS   -  Reactive oxygen species 
RT3   -  Reverse Triiodothyronine 
RXR   -  Retinoid X Receptor    
SLE   -  Systemic Lupus Erythematosus 
TBG   -  Thyroxine Binding Globulin  
TG   -  Thyroglobulin              
TPO   -  Thyroid  Peroxidase           
TRE   -  Thyroid hormone Response Elements 
TRH   -  Thyrotropin - Releasing Hormone  
TR   -  Thyroid hormone Receptor 
TSH   -  Thyroid Stimulating Hormone                 
 
 
 
 
 
 
 
INFORMATION SHEET 
 
TITLE : 
“ASSESSMENT OF THYROID FUNCTION IN PATIENTS WITH 
SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS  
CLINICAL CORRELATION” 
 
Name of Investigator  :     Name of Participant : 
 
Purpose of Research :  Assessment of  thyroid function in patients with 
SLE and its clinical correlation . 
 
Study Design  :Prospective Observational Study 
 
Study Procedures :Patient will be subjected to routine investigations, 
Chest X ray, ANA , Anti ds -DNA& USG neck & free T3, freeT4, TSH 
and outcomes analysed 
 
Possible Risks :No risks to the patient 
 
Possible benefits 
 
To patient  : Patient is provided a means of assessing the pathology 
their disease and also as a means of early identification. 
 
To doctor & to other people  : If this study gives positive results, it can 
help to emphasize the role of routine thyroid function testing in patients 
with SLE. This will help in providing better and early diagnosis to other 
patients in future. 
Confidentiality of the information obtained from you :The privacy of the 
patients in the research will be maintained throughout the study. In the event 
of any publication or presentation resulting from the research, no personally 
identifiable information will be shared 
Can you decide to stop participating in the study :Taking part in this 
study is voluntary. You are free to decide whether to participate in this study 
or to withdraw at any time 
How will your decision to not participate in the study affect you :Your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
 
Signature of Investigator:         Signature of the participant:            
 
Date : 
Place : 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
Study Detail : 
    “ASSESSMENT OF THYROID FUNCTION IN      
    PATIENTS WITH SYSTEMIC LUPUS  
    ERYTHEMATOSUS AND ITS  
    CLINICAL CORRELATION” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. ❏ 
 
Signature/thumb impression 
 
Patient’s Name and Address: 
Signature of Investigator 
Study Investigator’s Name : 
Dr.VELVIZHI.M 
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1 23 F 95727 2 - - - - - - - - - - - 9 N N + + 0.4 1.3 8.4 N
2 23 F 94123 1 - - - - - - - - - - - 9.4 N N + + 0.3 1.4 7.6 N
3 37 F 96493 5 - - - - - - - - - - - 8.1 N N + + 0.2 1 9.3 N
4 27 F 96963 2 - - - + - - - - - - - 7.5 N N + + 0.4 1.3 4.1 N
5 24 F 92275 NEW - + - - - - - - - - - 10.2 N N + + 0.7 0.9 2.5 N
6 19 F 94551 NEW - + - - - - - - - - - 9.6 N N + + 0.5 1.5 3.1 N
7 15 F 60439 1 - - - - - - - - - - - 8.9 N N + + 0.3 1.1 4 CYST
8 16 F 87403 1 - - - - - - - - - - - 6.2 N N + + 0.6 1.7 3.5 N
9 37 F 97051 6 + - - - - - - - C + + 7.9 N PE + + 0.01 0.2 16.4 N
10 48 F 43886 5 + - - - + - - - - - - 8 N N + + 0.3 0.9 1.8 N
11 21 F 59681 3 - + - - - - - - - - - 8.4 N N + + 0.5 1.2 2.6 N
12 29 F 57107 4 - - - - - - - - - - - 7.9 N N + + 0.2 1.5 8.7 N
13 17 F 65390 1 - - - - + - - - - - - 5.7 N N + + 0.6 1.8 2.9 N
14 20 F 80727 2 - + - - + - - - - - - 9.7 N N + + 0.4 1.4 3.6 N
15 26 F 81507 NEW - + - - - - - - - - - 10 N N + + 0.5 1.1 4 N
16 22 F 80224 NEW - - - - - - - - - - - 10.5 N N + + 0.7 0.9 3.1 N
17 30 F 81229 4 + - - + - - - - - - - 8.6 N N + + 0.2 1.2 1.8 N
18 26 F 79861 3 - - - - - - - - - - - 9.2 N N + + 0.4 1.1 8.3 N
19 34 F 76549 5 - + - - + + - - - - - 8.1 N N + + 0.5 1.6 3.2 N
20 32 F 79012 NEW - + - - - - - + - - - 10.5 N N + + 0.3 1.4 3.5 N
21 21 F 77834 2 - + - - - - - - - + - 11 N N + + 0.4 1.6 2.1 N
22 19 F 71290 1 - - - - - - - - - - - 9.7 N N + + 0.5 1.3 4.2 N
23 28 F 87652 4 + - - + - - - + C - - 6.2 N N + + 0.02 0.1 17.6 N
24 23 F 65437 3 - - - - - - + - - - - 9.1 N N + + 0.7 1 4.3 N
25 36 F 72983 7 - - - - - - - - - - - 9 N N + + 0.3 1.2 9.3 N
26 40 F 66782 6 + - - - - - - - - - - 10.2 N N + + 0.5 1.7 3.7 N
27 17 F 69354 1 - - - - - - - - - - - 9.6 N N + + 0.8 1.2 2.9 N
28 24 F 71098 4 - + - - - - - + - - - 8.7 N N + + 0.2 0.9 2.4 N
29 29 F 70145 3 + - - - + - - - - - + 7.4 N PE + + 0.03 1.1 21.6 N
30 38 F 71652 5 + - - - - - - - - + + 10 N N + + 0.6 1.4 2.1 N
31 19 F 68340 2 - - - - - - - - - - - 9.8 N N + + 0.2 1 3.7 N
32 27 F 67891 1 - - - - - - - - - - - 11.2 N N + + 0.4 1.5 3.1 N
33 36 F 57198 2 - - - + - - - - - + - 7.5 N N + + 0.01 0.3 18.3 N
34 31 F 60917 4 + - - - - - - - - - - 8.4 N N + + 0.3 1.8 4 N
35 26 F 71453 8 + - - - - - - + - - + 9 N N + + 0.5 1 3.2 N
36 42 F 79821 5 - - - - - - - - - - - 8.1 N N + + 0.4 1.5 8.1 N
37 30 F 64097 3 - - - - - - - - - - - 10.3 N N + + 0.6 1.6 4 N
38 24 F 78431 3 - - - + - - - - - - - 11 N N + + 0.2 1.8 3.2 N
39 22 F 65210 1 - - - + - - - - - - - 10.7 N N + + 0.7 1.1 2.5 N
40 27 F 56983 3 - - - - - - - - - - + 7.1 N N + + 0.2 1.4 9.4 N
41 35 F 59820 2 - + - - - - + - - - - 10.4 N N + + 0.5 1.9 4.3 N
42 34 F 57531 NEW - - - - - - - - - - - 9.8 N N + + 0.3 1.2 3.5 N
43 31 F 70369 4 + - - - - - - - - - - 8.7 N N + + 0.7 1.7 2.8 N
44 18 F 67891 1 - - - - - - - - - - - 9.5 N N + + 0.4 1.5 1.8 N
45 16 F 58341 2 - - - - - - - - - - - 10.9 N N + + 0.2 1 3.9 N
46 43 F 60118 6 + - - - - - - + - - - 8.2 N N + + 0.6 0.9 4.3 N
47 37 F 62871 5 + - - - + - - - - + - 7.6 N N + + 0.5 1.6 4 N
48 34 F 66439 2 - - - - - - - - C - - 10.2 N N + + 0.4 1.8 2.6 N
49 25 F 73209 3 - - - - - - - - D - - 9.1 N N + + 0.3 1.1 3.1 N
50 28 F 42801 4 - - - - - - - - - - - 6.8 N N + + 0.3 1.2 7.9 N
51 20 F 65320 1 - - - + - - - - - - - 11.6 N N + + 0.2 0.9 3.9 N
52 33 F 58720 6 - - - - - - - - - - + 9.5 N N + + 0.4 1.6 2.1 N
53 30 F 59014 4 - - - - - - + - - - - 8.9 N N + + 0.02 0.3 15.6 N
54 29 F 51987 NEW - - - + - - - - - - - 11.2 N N + + 0.5 1.4 4 N
55 34 F 73982 4 - - - + - - - - - - - 9.8 N N + + 0.1 1.1 3.4 N
56 40 F 49824 7 + - - - - - - - - + - 11 N N + + 0.3 1.8 2.9 N
57 36 F 69320 5 + - - - - - - - - - - 7.6 N N + + 0.6 0.9 3.1 N
58 32 F 79381 2 - + - - - - - - - - - 9 N N + + 0.7 1.1 2.6 N
59 29 F 71024 1 - - - - - - - - - - - 10.8 N N + + 0.4 1.2 1.8 N
60 27 F 64689 3 - - - - + - - + D - - 11 N N + + 0.3 1.7 4.3 N
61 31 F 69317 4 - - - - - - - - - - - 9.2 N N + + 0.2 1.3 8.6 N
62 21 F 53901 NEW - - - - - - - - - - - 10.6 N N + + 0.4 1.5 4.2 N
63 28 F 50487 3 - - - - - - - - - - + 9.9 N N + + 0.2 1.6 9.1 N
64 36 F 42903 4 - - - - - - - - - - - 10.1 N N + + 0.3 1.2 8.9 N
65 41 F 43691 1 - - - - - - - - - - 11.6 N N + + 0.6 1.9 3.7 N
66 43 F 46182 5 + - - - - - - + C - - 9.8 N N + + 0.2 1.7 2.8 N
67 25 F 49710 3 - - - - - - - - - - - 8.5 N N + + 0.5 0.9 3.5 N
68 22 F 40153 NEW - - + + - - - + - - - 10.6 N N + + 0.1 1.3 2.1 N
69 20 F 58670 2 - - + + - - - - - - - 9.1 N N + + 0.4 1.8 4.3 N
70 19 F 53804 3 - - - - - - - - - - - 11.4 N N + + 0.8 1.5 3 N
71 39 F 40183 6 - - - - - - - - - - + 8.3 N N + + 0.3 1 1.9 N
72 33 F 39568 4 - - - - - - - - - - + 9 N N + + 0.4 0.9 9.4 N
73 26 F 33982 NEW - - - - - - - - - - - 10.6 N N + + 0.2 1.4 4.7
74 18 F 60173 NEW - - - - - - - + - - - 9.5 N N + + 0.5 1.2 4 N
75 25 F 50914 1 - - - - - - - - - - - 11.6 N N + + 0.7 1.7 3.4 N
76 24 F 79801 4 + - - - - - - - - - - 10 N N + + 0.1 1.2 4.1 N
77 22 F 40913 2 - - - - - - - - - - - 9.7 N N + + 0.4 0.9 3.6 N
78 20 F 44071 NEW - - - - - - - - - - - 12 N N + + 0.2 1 1.9 N
79 19 F 38619 4 - + - - - - - - - - - 7.9 N N + + 0.5 1.3 4..0 N
80 29 F 32901 3 - - - + - - + - - - + 8.2 N PE + + 0.02 0.1 26.4 N
81 33 F 49281 2 - - - - - - - - - - - 11 N N + + 0.3 1.8 4.2 N
82 30 F 45938 2 - - - - - - - + - - - 10.1 N N + + 0.1 1.5 3.6 N
83 27 F 75130 5 + - - - - - - - - + - 8 N N + + 0.4 1.8 3.9 N
84 21 F 70912 NEW - - - - - - - - - - - 7.1 N N + + 0.3 1.1 2.8 N
85 29 F 52016 3 - - - - - - - - - - - 8.2 N N + + 0.1 1.6 7.2 N
86 35 F 59203 NEW - - - - - - - - - - - 11.6 N N + + 0.4 1.3 4 N
87 37 F 56715 4 - - - - - - - - - - - 8.1 N N + + 0.6 1.7 4.1 N
88 26 F 51082 3 + - - - - - - - - - + 7 N N + + 0.01 0.2 21.4 N
89 18 F 49310 1 - - - - - - - - - - - 6.9 N N + + 0.4 1 2.9 N
90 34 F 48731 2 - - - + - - - - - - - 10.7 N N + + 0.5 1.5 3.6 N
91 41 F 30017 6 - - - - + - + - - - - 9 N N + + 0.2 1.9 4.2 N
92 34 F 39163 5 - - - - - - - - - - + 9.5 N N + + 0.4 0.9 9.6 N
93 23 F 37610 3 - - - - - - - - - - - 8.6 N N + + 0.5 1.2 3.9 N
94 36 F 30926 4 + - - - - + - - - - - 7.9 N N + + 0.2 1.5 4.1 N
95 31 F 87431 2 - + - - - - - + - - - 11 N N + + 0.3 1.3 4.2 N
96 30 F 80327 1 - - - - - - - - - - - 12 N N + + 0.4 1.2 3.7 N
97 26 F 71205 3 - - - - - - - - - - - 9.7 N N + + 0.2 1 8.5 N
98 29 F 76204 1 - - - - - - - - - - - 8.9 N N + + 0.5 1.4 4 N
99 38 F 56292 4 + - - - - + - - - - - 10.2 N N + + 0.4 1.6 3.8 N
100 17 F 43209 NEW - - - - - - - - - - - 11.4 N N + + 0.5 1.2 2.7 N
C- CONSTIPATION   , D- DIARRHOEA, PE - PLEURAL EFFUSION,   N - NORMAL
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
